BONESUPPORT Earns Frost & Sullivan's 2015 Best Practices Award For Its Novel Product, CERAMENT™

CERAMENT™ making inroads into infection management market with sustained release of antibiotics

LUND, Sweden, May 13, 2015 /CNW/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in the orthopedic biomaterial market with its proprietary product, CERAMENT™.  CERAMENT™ is a platform technology currently available under four product lines:  CERAMENT™|G, CERAMENT™|V, CERAMENT™|BONE VOID FILLER and CERAMENT™| SPINE SUPPORT.  CERAMENT™|G and CERAMENT™|V are the only approved injectable bone substitutes with antibiotics indicated to promote and protect bone healing in the management of bone infection.

"This award represents valuable third party validation and we are honored to receive this global recognition from Frost & Sullivan," said Lloyd Diamond, CEO of BONESUPPORT.   "We believe CERAMENT™, with its unique bone remodeling capabilities and its ability to prevent colonization of sensitive microorganisms onto implanted devices, represents the next step in the management of bone infection, as well as holding significant promise in drug eluting delivery with applications extending beyond the orthopedic market."

CERAMENT™|G and CERAMENT™|V are intended to prevent colonization of sensitive microorganisms, thereby protecting the bone healing, particularly in challenging cases of deep bone infection.  Osteomyelitis, or Bone Infection is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries, and an increasing resistance to antibiotics contribute to this growing condition.

Frost & Sullivan's Senior Research Analyst, Dr. E. Saneesh said, " BONESUPPORT's products are making inroads into the infection management market by addressing the challenges with its patented technology platform, CERAMENT™.  This technology aids the sustained release of antibiotics, and resolves key issues such as infection management and delays in bone healing."

The 2015 Frost & Sullivan Best Practices Award is presented annually to the company that demonstrates outstanding achievement and superior performance in technological innovation, strategic product development and leadership.  Industry analysts compare market participants and measures performance through in-depth interviews, analysis and extensive secondary research.  A copy of the award report is available at:  https://www.bonesupport.com/en-eu/about-bonesupport/investor-information/frost-and-sullivans-2015.html

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT™|G and CERAMENT™|V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G and CERAMENT™|V are not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENT™ is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 10,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
[email protected]
Phone [phone]

PR 0429-01 en

SOURCE BONESUPPORT